- Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition - - Cash, cash ...

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug ...

Sutro Biopharma (NASDAQ:STRO) said on Thursday that, under its portfolio review, the company has decided to advance its dual-payload ADC programs, while deprioritizing development of luveltamab ...

- Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner - - Three INDs for ...

Sutro Biopharma will cut its workforce by half after completing a strategic review of the company's portfolio. Its top executive will also step down, as it switches focus to its next-generation ...

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago.

SOUTH SAN FRANCISCO - Sutro Biopharma, Inc. (NASDAQ: STRO), a company specializing in antibody drug conjugates (ADCs) for oncology, has announced a strategic shift in its pipeline focus ...

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody ...

Explore Sutro Biopharma stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for STRO. Sutro Biopharma reported $62 million in 2024 revenue, down from $153.7 ...

In a decisive moment of the Champions Trophy semi-final, KL Rahul boosted India's chances by advising Virat Kohli to bat smart, but Kohli's uncharacteristic dismissal almost jeopardised the game.